Similarly, a dual SPHK1/2 inhibitor developed by Amgen, “Compound A”, did not inhibit cancer cell proliferation or survival and had no effect as a single agent in a mouse breast cancer xenograft model, at concentrations where S1P synthesis was effectively blocked [14]. Here, SPHK1 is linked to breast carcinoma.